Phase II study of ?2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)-Reference-Cited by-同舟云学术

Phase II study of ?2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)

Published:2003-06-18 Issue:1 Volume:98 Page:100-109
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Radin Arthur I.,Kim Haesook T.,Grant Barbara W.,Bennett John M.,Kirkwood John M.,Stewart James A.,Hahn Richard G.,Dutcher Janice P.,Wiernik Peter H.,Oken Martin M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference59 articles.

1. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia

2. Side Effects of Long-Term Treatment with Human Leukocyte Interferon

3. Toxicity of interferon.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Progress in Interferon Therapy for Myeloid Malignancies;Frontiers in Oncology;2021-10-29

2. Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms;Expert Review of Hematology;2021-08-20

3. Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis;International Journal of Hematology;2021-06-06

4. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis;Leukemia;2020-09-01

5. Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature;Cancers;2020-07-18